Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT07619911 Sponsor: Fudan University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT07619911
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older, of any gender.
  • People whose general health and ability to carry out daily activities meets a certain standard, rated 0 or 1 on a medical scale used by doctors to assess this (confirm with trial site).
  • People who have been diagnosed through a lab test with a type of lung cancer called non-small-cell lung cancer (NSCLC) that cannot be removed by surgery and is classified as stage III.
  • People with a life expectancy of at least 3 months.
  • People who have not previously received any anti-cancer treatment for this condition.
  • People who do not have certain specific gene changes (known as EGFR, ALK, or ROS1 mutations) that can affect how some lung cancers behave.
  • People who have at least one tumour that can be measured using standard imaging guidelines.
  • People whose liver, kidneys, and other organs are functioning at an adequate level (confirm with trial site).
  • People who have read and signed a form agreeing to take part in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose lung cancer has features of both small-cell and non-small-cell types mixed together.
  • People who have the specific gene changes known as EGFR, ALK, or ROS1 mutations.
  • People who have received systemic anti-cancer treatment within the past 4 weeks.
  • People who have an autoimmune disease that is currently active and requires ongoing medical treatment.
  • People who have an active infection, including uncontrolled hepatitis B, hepatitis C, or HIV.
  • People who have a serious heart or blood vessel condition.
  • People whose blood pressure is not well controlled.
  • People who are pregnant or currently breastfeeding.
  • People who are already taking part in another clinical trial that involves a treatment intervention.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026

Contact this trial

Phone: +8618017312901

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 July 2028

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov